Belite Bio (BLTE) Liabilities and Shareholders Equity (2021 - 2026)

Belite Bio's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $811.3 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 394.07% year-over-year to $811.3 million; the TTM figure through Mar 2026 stood at $2.0 billion (up 268.81% YoY), while the FY2025 annual figure was $780.6 million, up 413.08% from the prior year.
• Liabilities and Shareholders Equity was $811.3 million for Q1 2026 at Belite Bio, up from $780.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $811.3 million in Q1 2026 to a low of $39.8 million in Q1 2023.
• Historically, Liabilities and Shareholders Equity has averaged $212.8 million across 5 years, with a median of $117.1 million in 2024.
• Biggest YoY gain for Liabilities and Shareholders Equity was 413.08% in 2025; the steepest drop was 32.07% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $44.3 million in 2022, then surged by 113.77% to $94.6 million in 2023, then jumped by 60.74% to $152.1 million in 2024, then soared by 413.08% to $780.6 million in 2025, then gained by 3.94% to $811.3 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $811.3 million (Q1 2026), $780.6 million (Q4 2025), and $282.4 million (Q3 2025), per Business Quant data.